Replies to post #293101 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

From the Jan Corp deck:
“ Top-line data EXCELLENCE: Potentially pivotal Phase 2/3 pediatric RTT clinical trial – expected 2H 2021”

The change to pivotal P2/3 puts readout into H2 2021, I suspect because more patients will be enrolled than first planned.

[ExtremelyBullishZig]

He needs that information for fluff PRs later. This way you can't buy options timed for data release if you don't know when it will happen. But he can put PRs out when the stock gets too close to $5. It's too hard to dilute when you don't control the flow of information. This allows him to drop those press releases when he needs to raise capital. Anyone who doesn't believe this is nuts.